Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes
Abstract Introduction The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope213 Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi 3 + ,...
Gespeichert in:
Veröffentlicht in: | Nuclear medicine and biology 2015-05, Vol.42 (5), p.428-438 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 438 |
---|---|
container_issue | 5 |
container_start_page | 428 |
container_title | Nuclear medicine and biology |
container_volume | 42 |
creator | Wilson, Justin J Ferrier, Maryline Radchenko, Valery Maassen, Joel R Engle, Jonathan W Batista, Enrique R Martin, Richard L Nortier, Francois M Fassbender, Michael E John, Kevin D Birnbaum, Eva R |
description | Abstract Introduction The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope213 Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi 3 + , however, hinders the development of bifunctional chelating agents that can successfully deliver these Bi radioisotopes to the tumor cells. Here, a novel series of nitrogen-rich macrocyclic ligands is explored for their potential use as Bi-selective chelating agents. Methods The ligands, 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy ), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyd ), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyr ), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (Lpz ), were prepared by a previously reported method and investigated here for their abilities to bind Bi radioisotopes. The commercially available and commonly used ligands 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and N -[( R )-2-amino-3-( p -isothiocyanato-phenyl)propyl]- trans -( S,S )- cyclohexane-1,2-diamine- N , N , N ', N ", N "-pentaacetic acid (CHX-A′′-DTPA) were also explored for comparative purposes. Radio-thin-layer chromatography (TLC) was used to measure the binding kinetics and stabilities of the complexes formed. The long-lived isotope,207 Bi (t1/2 = 32 years), was used for these studies. Density functional theory (DFT) calculations were also employed to probe the ligand interactions with Bi 3 + and the generator parent ion Ac 3 +. Results In contrast to DOTA and CHX-A′′-DTPA, these nitrogen-rich macrocycles selectively chelate Bi 3 + in the presence of the parent isotope Ac 3 + . Among the four tested, Lpy was found to exhibit optimal Bi 3 + -binding kinetics and complex stability. Lpy complexes Bi 3 + more rapidly than DOTA, yet the resulting complexes are of similar stability. DFT calculations corroborate the experimentally observed selectivity of these ligands for Bi 3 + over Ac 3 +. Conclusion Taken together, these data implicate Lpy as a valuable chelating agent for the delivery of213 Bi. Its selectivity for Bi 3 + and rapid and stable labeling properties warrant further investigation and biological studies. |
doi_str_mv | 10.1016/j.nucmedbio.2014.12.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_1193399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0969805114005721</els_id><sourcerecordid>1671211331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-47130a8548759bd0b0a66ef481d23e0cf858aa7cd211eaf938a4296d818bd733</originalsourceid><addsrcrecordid>eNqNkkFv1DAQhS0EotvCX4CIE5cET5w4zgWpqgpFqsSB3i3HnjReEnuxnUr77-toyx44cbI0_t7M6L0h5CPQCijwL_vKrXpBM1hf1RSaCuqK0u4V2YHo6rLn0LwmO9rzvhS0hQtyGeOeZmUD9C25qFsuGt7SHRlvn9S8qmS9K_xYOJuCf0RXBqunYlE6eH3Us9XFbB-VM7EYfSjShIWecD7LciGoA64pg4ONy5qmIihjvY0--QPGd-TNqOaI71_eK_Lw7fbh5q68__n9x831fanbrk5l0wGjSrSN6Np-MHSginMcGwGmZkj1KFqhVKdNDYBq7JlQTd1zI0AMpmPsinw6tfUxWRm1Tagn7Z1DnSRAz1jfZ-jzCToE_2fFmORio8Z5Vg79GiXwDnJ_xiCj3QnNPsQYcJSHYBcVjhKo3IKQe3kOQm5BSKhlDiIrP7wMWYf8fdb9dT4D1ycAsx1PFsO2LjqNxoZtW-Ptfwz5-k-PHJWzWs2_8Yhx79fgstsSZMwC-Wu7h-0coKE0-w3sGe18s-c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1671211331</pqid></control><display><type>article</type><title>Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wilson, Justin J ; Ferrier, Maryline ; Radchenko, Valery ; Maassen, Joel R ; Engle, Jonathan W ; Batista, Enrique R ; Martin, Richard L ; Nortier, Francois M ; Fassbender, Michael E ; John, Kevin D ; Birnbaum, Eva R</creator><creatorcontrib>Wilson, Justin J ; Ferrier, Maryline ; Radchenko, Valery ; Maassen, Joel R ; Engle, Jonathan W ; Batista, Enrique R ; Martin, Richard L ; Nortier, Francois M ; Fassbender, Michael E ; John, Kevin D ; Birnbaum, Eva R ; Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)</creatorcontrib><description>Abstract Introduction The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope213 Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi 3 + , however, hinders the development of bifunctional chelating agents that can successfully deliver these Bi radioisotopes to the tumor cells. Here, a novel series of nitrogen-rich macrocyclic ligands is explored for their potential use as Bi-selective chelating agents. Methods The ligands, 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy ), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyd ), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyr ), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (Lpz ), were prepared by a previously reported method and investigated here for their abilities to bind Bi radioisotopes. The commercially available and commonly used ligands 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and N -[( R )-2-amino-3-( p -isothiocyanato-phenyl)propyl]- trans -( S,S )- cyclohexane-1,2-diamine- N , N , N ', N ", N "-pentaacetic acid (CHX-A′′-DTPA) were also explored for comparative purposes. Radio-thin-layer chromatography (TLC) was used to measure the binding kinetics and stabilities of the complexes formed. The long-lived isotope,207 Bi (t1/2 = 32 years), was used for these studies. Density functional theory (DFT) calculations were also employed to probe the ligand interactions with Bi 3 + and the generator parent ion Ac 3 +. Results In contrast to DOTA and CHX-A′′-DTPA, these nitrogen-rich macrocycles selectively chelate Bi 3 + in the presence of the parent isotope Ac 3 + . Among the four tested, Lpy was found to exhibit optimal Bi 3 + -binding kinetics and complex stability. Lpy complexes Bi 3 + more rapidly than DOTA, yet the resulting complexes are of similar stability. DFT calculations corroborate the experimentally observed selectivity of these ligands for Bi 3 + over Ac 3 +. Conclusion Taken together, these data implicate Lpy as a valuable chelating agent for the delivery of213 Bi. Its selectivity for Bi 3 + and rapid and stable labeling properties warrant further investigation and biological studies.</description><identifier>ISSN: 0969-8051</identifier><identifier>EISSN: 1872-9614</identifier><identifier>DOI: 10.1016/j.nucmedbio.2014.12.007</identifier><identifier>PMID: 25684650</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Actinium - chemistry ; Actinium-225 ; Alpha Particles - therapeutic use ; Binding, Competitive ; Bismuth - chemistry ; Bismuth - therapeutic use ; Bismuth-213 ; Chelating Agents - chemistry ; Edetic Acid - chemistry ; Isotope Labeling ; Kinetics ; Ligands ; Macrocycles ; Macrocyclic Compounds - chemistry ; Nitrogen - chemistry ; Quantum Theory ; Radio-thin-layer chromatography ; Radioisotopes ; Radiolabeling ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Targeted α-therapy</subject><ispartof>Nuclear medicine and biology, 2015-05, Vol.42 (5), p.428-438</ispartof><rights>2014</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-47130a8548759bd0b0a66ef481d23e0cf858aa7cd211eaf938a4296d818bd733</citedby><cites>FETCH-LOGICAL-c572t-47130a8548759bd0b0a66ef481d23e0cf858aa7cd211eaf938a4296d818bd733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0969805114005721$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25684650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/servlets/purl/1193399$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilson, Justin J</creatorcontrib><creatorcontrib>Ferrier, Maryline</creatorcontrib><creatorcontrib>Radchenko, Valery</creatorcontrib><creatorcontrib>Maassen, Joel R</creatorcontrib><creatorcontrib>Engle, Jonathan W</creatorcontrib><creatorcontrib>Batista, Enrique R</creatorcontrib><creatorcontrib>Martin, Richard L</creatorcontrib><creatorcontrib>Nortier, Francois M</creatorcontrib><creatorcontrib>Fassbender, Michael E</creatorcontrib><creatorcontrib>John, Kevin D</creatorcontrib><creatorcontrib>Birnbaum, Eva R</creatorcontrib><creatorcontrib>Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)</creatorcontrib><title>Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes</title><title>Nuclear medicine and biology</title><addtitle>Nucl Med Biol</addtitle><description>Abstract Introduction The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope213 Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi 3 + , however, hinders the development of bifunctional chelating agents that can successfully deliver these Bi radioisotopes to the tumor cells. Here, a novel series of nitrogen-rich macrocyclic ligands is explored for their potential use as Bi-selective chelating agents. Methods The ligands, 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy ), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyd ), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyr ), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (Lpz ), were prepared by a previously reported method and investigated here for their abilities to bind Bi radioisotopes. The commercially available and commonly used ligands 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and N -[( R )-2-amino-3-( p -isothiocyanato-phenyl)propyl]- trans -( S,S )- cyclohexane-1,2-diamine- N , N , N ', N ", N "-pentaacetic acid (CHX-A′′-DTPA) were also explored for comparative purposes. Radio-thin-layer chromatography (TLC) was used to measure the binding kinetics and stabilities of the complexes formed. The long-lived isotope,207 Bi (t1/2 = 32 years), was used for these studies. Density functional theory (DFT) calculations were also employed to probe the ligand interactions with Bi 3 + and the generator parent ion Ac 3 +. Results In contrast to DOTA and CHX-A′′-DTPA, these nitrogen-rich macrocycles selectively chelate Bi 3 + in the presence of the parent isotope Ac 3 + . Among the four tested, Lpy was found to exhibit optimal Bi 3 + -binding kinetics and complex stability. Lpy complexes Bi 3 + more rapidly than DOTA, yet the resulting complexes are of similar stability. DFT calculations corroborate the experimentally observed selectivity of these ligands for Bi 3 + over Ac 3 +. Conclusion Taken together, these data implicate Lpy as a valuable chelating agent for the delivery of213 Bi. Its selectivity for Bi 3 + and rapid and stable labeling properties warrant further investigation and biological studies.</description><subject>Actinium - chemistry</subject><subject>Actinium-225</subject><subject>Alpha Particles - therapeutic use</subject><subject>Binding, Competitive</subject><subject>Bismuth - chemistry</subject><subject>Bismuth - therapeutic use</subject><subject>Bismuth-213</subject><subject>Chelating Agents - chemistry</subject><subject>Edetic Acid - chemistry</subject><subject>Isotope Labeling</subject><subject>Kinetics</subject><subject>Ligands</subject><subject>Macrocycles</subject><subject>Macrocyclic Compounds - chemistry</subject><subject>Nitrogen - chemistry</subject><subject>Quantum Theory</subject><subject>Radio-thin-layer chromatography</subject><subject>Radioisotopes</subject><subject>Radiolabeling</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Targeted α-therapy</subject><issn>0969-8051</issn><issn>1872-9614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkFv1DAQhS0EotvCX4CIE5cET5w4zgWpqgpFqsSB3i3HnjReEnuxnUr77-toyx44cbI0_t7M6L0h5CPQCijwL_vKrXpBM1hf1RSaCuqK0u4V2YHo6rLn0LwmO9rzvhS0hQtyGeOeZmUD9C25qFsuGt7SHRlvn9S8qmS9K_xYOJuCf0RXBqunYlE6eH3Us9XFbB-VM7EYfSjShIWecD7LciGoA64pg4ONy5qmIihjvY0--QPGd-TNqOaI71_eK_Lw7fbh5q68__n9x831fanbrk5l0wGjSrSN6Np-MHSginMcGwGmZkj1KFqhVKdNDYBq7JlQTd1zI0AMpmPsinw6tfUxWRm1Tagn7Z1DnSRAz1jfZ-jzCToE_2fFmORio8Z5Vg79GiXwDnJ_xiCj3QnNPsQYcJSHYBcVjhKo3IKQe3kOQm5BSKhlDiIrP7wMWYf8fdb9dT4D1ycAsx1PFsO2LjqNxoZtW-Ptfwz5-k-PHJWzWs2_8Yhx79fgstsSZMwC-Wu7h-0coKE0-w3sGe18s-c</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Wilson, Justin J</creator><creator>Ferrier, Maryline</creator><creator>Radchenko, Valery</creator><creator>Maassen, Joel R</creator><creator>Engle, Jonathan W</creator><creator>Batista, Enrique R</creator><creator>Martin, Richard L</creator><creator>Nortier, Francois M</creator><creator>Fassbender, Michael E</creator><creator>John, Kevin D</creator><creator>Birnbaum, Eva R</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OIOZB</scope><scope>OTOTI</scope></search><sort><creationdate>20150501</creationdate><title>Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes</title><author>Wilson, Justin J ; Ferrier, Maryline ; Radchenko, Valery ; Maassen, Joel R ; Engle, Jonathan W ; Batista, Enrique R ; Martin, Richard L ; Nortier, Francois M ; Fassbender, Michael E ; John, Kevin D ; Birnbaum, Eva R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-47130a8548759bd0b0a66ef481d23e0cf858aa7cd211eaf938a4296d818bd733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Actinium - chemistry</topic><topic>Actinium-225</topic><topic>Alpha Particles - therapeutic use</topic><topic>Binding, Competitive</topic><topic>Bismuth - chemistry</topic><topic>Bismuth - therapeutic use</topic><topic>Bismuth-213</topic><topic>Chelating Agents - chemistry</topic><topic>Edetic Acid - chemistry</topic><topic>Isotope Labeling</topic><topic>Kinetics</topic><topic>Ligands</topic><topic>Macrocycles</topic><topic>Macrocyclic Compounds - chemistry</topic><topic>Nitrogen - chemistry</topic><topic>Quantum Theory</topic><topic>Radio-thin-layer chromatography</topic><topic>Radioisotopes</topic><topic>Radiolabeling</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Targeted α-therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilson, Justin J</creatorcontrib><creatorcontrib>Ferrier, Maryline</creatorcontrib><creatorcontrib>Radchenko, Valery</creatorcontrib><creatorcontrib>Maassen, Joel R</creatorcontrib><creatorcontrib>Engle, Jonathan W</creatorcontrib><creatorcontrib>Batista, Enrique R</creatorcontrib><creatorcontrib>Martin, Richard L</creatorcontrib><creatorcontrib>Nortier, Francois M</creatorcontrib><creatorcontrib>Fassbender, Michael E</creatorcontrib><creatorcontrib>John, Kevin D</creatorcontrib><creatorcontrib>Birnbaum, Eva R</creatorcontrib><creatorcontrib>Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV - Hybrid</collection><collection>OSTI.GOV</collection><jtitle>Nuclear medicine and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilson, Justin J</au><au>Ferrier, Maryline</au><au>Radchenko, Valery</au><au>Maassen, Joel R</au><au>Engle, Jonathan W</au><au>Batista, Enrique R</au><au>Martin, Richard L</au><au>Nortier, Francois M</au><au>Fassbender, Michael E</au><au>John, Kevin D</au><au>Birnbaum, Eva R</au><aucorp>Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes</atitle><jtitle>Nuclear medicine and biology</jtitle><addtitle>Nucl Med Biol</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>42</volume><issue>5</issue><spage>428</spage><epage>438</epage><pages>428-438</pages><issn>0969-8051</issn><eissn>1872-9614</eissn><abstract>Abstract Introduction The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope213 Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi 3 + , however, hinders the development of bifunctional chelating agents that can successfully deliver these Bi radioisotopes to the tumor cells. Here, a novel series of nitrogen-rich macrocyclic ligands is explored for their potential use as Bi-selective chelating agents. Methods The ligands, 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy ), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyd ), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyr ), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (Lpz ), were prepared by a previously reported method and investigated here for their abilities to bind Bi radioisotopes. The commercially available and commonly used ligands 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and N -[( R )-2-amino-3-( p -isothiocyanato-phenyl)propyl]- trans -( S,S )- cyclohexane-1,2-diamine- N , N , N ', N ", N "-pentaacetic acid (CHX-A′′-DTPA) were also explored for comparative purposes. Radio-thin-layer chromatography (TLC) was used to measure the binding kinetics and stabilities of the complexes formed. The long-lived isotope,207 Bi (t1/2 = 32 years), was used for these studies. Density functional theory (DFT) calculations were also employed to probe the ligand interactions with Bi 3 + and the generator parent ion Ac 3 +. Results In contrast to DOTA and CHX-A′′-DTPA, these nitrogen-rich macrocycles selectively chelate Bi 3 + in the presence of the parent isotope Ac 3 + . Among the four tested, Lpy was found to exhibit optimal Bi 3 + -binding kinetics and complex stability. Lpy complexes Bi 3 + more rapidly than DOTA, yet the resulting complexes are of similar stability. DFT calculations corroborate the experimentally observed selectivity of these ligands for Bi 3 + over Ac 3 +. Conclusion Taken together, these data implicate Lpy as a valuable chelating agent for the delivery of213 Bi. Its selectivity for Bi 3 + and rapid and stable labeling properties warrant further investigation and biological studies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25684650</pmid><doi>10.1016/j.nucmedbio.2014.12.007</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0969-8051 |
ispartof | Nuclear medicine and biology, 2015-05, Vol.42 (5), p.428-438 |
issn | 0969-8051 1872-9614 |
language | eng |
recordid | cdi_osti_scitechconnect_1193399 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Actinium - chemistry Actinium-225 Alpha Particles - therapeutic use Binding, Competitive Bismuth - chemistry Bismuth - therapeutic use Bismuth-213 Chelating Agents - chemistry Edetic Acid - chemistry Isotope Labeling Kinetics Ligands Macrocycles Macrocyclic Compounds - chemistry Nitrogen - chemistry Quantum Theory Radio-thin-layer chromatography Radioisotopes Radiolabeling Radiology RADIOLOGY AND NUCLEAR MEDICINE Targeted α-therapy |
title | Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A16%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20nitrogen-rich%20macrocyclic%20ligands%20for%20the%20chelation%20of%20therapeutic%20bismuth%20radioisotopes&rft.jtitle=Nuclear%20medicine%20and%20biology&rft.au=Wilson,%20Justin%20J&rft.aucorp=Los%20Alamos%20National%20Laboratory%20(LANL),%20Los%20Alamos,%20NM%20(United%20States)&rft.date=2015-05-01&rft.volume=42&rft.issue=5&rft.spage=428&rft.epage=438&rft.pages=428-438&rft.issn=0969-8051&rft.eissn=1872-9614&rft_id=info:doi/10.1016/j.nucmedbio.2014.12.007&rft_dat=%3Cproquest_osti_%3E1671211331%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1671211331&rft_id=info:pmid/25684650&rft_els_id=1_s2_0_S0969805114005721&rfr_iscdi=true |